These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 35038402)
1. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Qiu M Ann Intern Med; 2022 Jan; 175(1):W3-W4. PubMed ID: 35038402 [No Abstract] [Full Text] [Related]
2. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Patorno E; Htoo PT; Everett BM; Kim SC Ann Intern Med; 2022 Jan; 175(1):W4. PubMed ID: 35038405 [No Abstract] [Full Text] [Related]
3. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Patorno E; Htoo PT; Glynn RJ; Schneeweiss S; Wexler DJ; Pawar A; Bessette LG; Chin K; Everett BM; Kim SC Ann Intern Med; 2022 Jan; 175(1):W4-W5. PubMed ID: 35038404 [No Abstract] [Full Text] [Related]
4. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Bepo L; Makam AN; Nguyen OK Ann Intern Med; 2022 Jan; 175(1):W3. PubMed ID: 35038403 [No Abstract] [Full Text] [Related]
5. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. North EJ; Newman JD Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. Sharma A; Verma S Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes. Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101 [No Abstract] [Full Text] [Related]
8. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts. Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725 [TBL] [Abstract][Full Text] [Related]
11. New Antidiabetes Medications and Their Cardiovascular and Renal Benefits. Ferro EG; Elshazly MB; Bhatt DL Cardiol Clin; 2021 Aug; 39(3):335-351. PubMed ID: 34247748 [TBL] [Abstract][Full Text] [Related]
12. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease. Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708 [TBL] [Abstract][Full Text] [Related]
14. New Perspectives in Management of Cardiovascular Risk Among People With Diabetes. Gami A; Blumenthal RS; McGuire DK; Sarkar S; Kohli P J Am Heart Assoc; 2024 Jun; 13(12):e034053. PubMed ID: 38879449 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Scheen AJ Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368 [TBL] [Abstract][Full Text] [Related]
16. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. Lee MMY; Petrie MC; McMurray JJV; Sattar N Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025 [TBL] [Abstract][Full Text] [Related]
17. Sodium-Glucose Cotransporter 2 Inhibitors in Cardiovascular and Renal Outcomes in Patients With Diabetes but Without Established Cardiovascular Disease: A Nationwide Population-Based Cohort Study. Chang HC; Kuo TT; Chen YY; Lin YJ; Chang HY; Hung CL; Chung FP Diabetes Care; 2022 Sep; 45(9):129-130. PubMed ID: 35838320 [No Abstract] [Full Text] [Related]
18. Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A retrospective multi-institutional study. Hsiao FC; Lin CP; Tung YC; Wu CT; Chu PH Diabetes Res Clin Pract; 2021 Oct; 180():109076. PubMed ID: 34599973 [TBL] [Abstract][Full Text] [Related]
19. [Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines]. Kobalava ZD; Kokhan EV Kardiologiia; 2020 Oct; 60(9):122-133. PubMed ID: 33131483 [TBL] [Abstract][Full Text] [Related]
20. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]